Novartis AG (Basel, Switzerland) will withdraw its US
and European applications for approval of Zometa
(zoledronic acid) for the prevention of breast cancer
recurrence. The decision is based on the 5-year results
of the Adjuvant Zoledronic Acid to Redu…
PCCC Minimized Postop Axial Shift
The use of primary posterior continuous curvilinear
capsulorrhexis (PCCC) during cataract surgery stabilized and minimized axial IOL displacement.1
In a prospective, comparative study, researchers analyzed
data from 77 patients (86 eyes) who underwent …
Scorecard Helped Predict Visual Acuity After Cataract Surgery
A team of Spanish researchers has developed a scoring
tool to predict visual acuity and functional changes after
phacoemulsification, according to a report in
Ophthalmology.1
Emilio Perea-Milla, MD, PhD, of the Hospital de Marbella
in Málaga, Spain, a…
RENÉ LE BERRE, RIVER BLINDNESS PIONEER, DEAD AT 78
René Le Berre, PhD, an entomologist and
pioneer in the diagnosis and treatment of
river blindness, died on December 6, 2010,
in L’Aiguillon-sur-Mer, France, at the age of
78. Dr. Le Berre was responsible for preserving
the sight of millions of peopl…
Inflammation,Improved Visual Acuity in Uveitis With Ozurdex
The Ozurdex dexamethasone intravitreal implant
(Allergan, Inc.) significantly improved intraocular inflammation
and visual acuity in patients with noninfectious intermediate
or posterior uveitis, according to a study in the
Archives of Ophthalmology.1
…
New Indication for Ranibizumab Granted in EU
The European Commission has granted Novartis a new,
broader indication for ranibizumab (Lucentis; Genentech)
to treat patients with visual impairment due to diabetic
macular edema, according to a company news release.
The approval of Lucentis was based…